19.72PLN-0.70%Mkt Cap: 268.98M $P/E: 9.671d ago
Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, …
Industry Peers
Drug Manufacturers - Specialty & Genericvs Drug Manufacturers - Specialty & Generic
P/E
Cheaper
P/B
Avg
1M Perf
Higher
Indicators:|
Key Statistics
Company
Market Cap268.98M $
Enterprise Value280.27M $
Revenue (TTM)57.14M $
Gross Profit39.04M $
Net Income (TTM)-20.10M $
Revenue/Share1.098 USD
Last Price19.72 PLN
Fiscal Year EndDec 2024
MR QuarterMar 2026
Employees564
CountryPL
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINPLCLNPH00015
Valuation
P/E (Trailing)9.67
P/E (Forward)12.32
PEG—
EV/EBITDA-12.86
EV/Revenue4.91
P/S4.71
P/B2.01
EPS (TTM)2.04
EPS (Forward)1.60
52W Range
18.5018% of range25.30
52W High25.30 PLN
52W Low18.50 PLN
Profitability
Gross Margin68.32%
Oper. Margin-9.75%
EBITDA Margin-38.14%
Profit Margin-54.25%
ROE-21.85%
ROA-17.35%
Growth
Revenue Growth24.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF6.04M $
CapEx (TTM)—
FCF Margin-34.02%
FCF Yield-7.23%
Net Debt11.29M $
Net Debt/EBITDA-0.52
Balance Sheet
Debt/Equity10.15
Current Ratio1.90
Quick Ratio1.38
Book Value/Sh9.818 PLN
Cash/Share0.1690 PLN
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 PLN
Div. Yield—
5Y Avg Yield0.68%
Payout Ratio0.00%
Ex-Div DateJun 27, 2024
Pay Date—
Analyst Consensus
Rating—
Target (Mean)20.44 PLN
Upside (mean)+3.7%
Target Range16.00 PLN – 25.50 PLN
PLN16.00+3.7% to meanPLN25.50
# Analysts5
Ownership
Shares Out.53.86M
Float23.82M
Insiders55.70%
Institutions18.00%
Technical
SMA 5020.78 (-5.1%)
SMA 20021.28 (-7.3%)
Beta0.67
S&P 52W Chg20.05%
Avg Vol (30d)10.04K
Avg Vol (10d)8.43K
Technical Indicators
RSI (14)36.3
MACD-0.3007
MACD Signal-0.2128
MACD Hist.-0.0879
BB Upper21.49 PLN
BB Middle20.44 PLN
BB Lower19.38 PLN
BB Width10.29%
ATR (14)0.5053 PLN
Vol Ratio (20d)1.08x